Marcus Conant, MD, on More Research Needed With HIV Therapies

Commentary
Video

The Chief Medical Officer of Addimmune discussed the unmet need with HIV and research the company is conducting.

“We need a new approach to treating this disease. We've got ways of blocking the virus, but it requires taking a pill each day for the rest of your life. And that creates a huge barrier for many people. Can they afford them? Can they remember to get them, are they available? And on and on? Or do the drugs not work for those patients? We think that [our] approach will be life saving for future patients.”

AGT103-T (Addimmune, a subsidiary of American Gene Technologies) gene therapy, when combined with multiple analytical treatment interruptions (ATI), was well-tolerated and demonstrated viral control in people with human immunodeficiency virus (HIV), according to a paper published in Frontiers in Medicine. Six of 7 participants previously infused with the gene therapy in a phase 1 study (NCT04561258) were enrolled into a second ATI study (NCT05540964). Investigators found that viral setpoints were consistently below 25,000 copies/mL and participants had relatively stable CD4 T cell counts in all participants that had 1 ATI in the study and 4 that had 2 ATIs.

CGTLive® spoke with Marcus Conant, MD, Chief Medical Officer of Addimmune, to learn more about the candidates the company is developing for treating HIV, including AGT103-T and other programs in the pipeline. He also emphasized the need for novel treatments for people with HIV, as around 40,000 people in the US are not eligible for current treatments and more outside the US do not have easy access to these treatments.

REFERENCE
Jain A, Canepa GE, Liou ML, et al. Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral control. Front. Med. 2024. Sec. Infectious Diseases: Pathogenesis and Therapy (11). doi: 10.3389/fmed.2024.1342476
Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.